BrainCheck vs Cognivue (2026)
Two of the most credible records in cognitive assessment, split by regulatory weight against practical fit. Cognivue is the category's originator: it holds the De Novo classification that created the regulatory pathway every later computerised cognitive test was cleared into, its adaptive psychophysics is genuine computation rather than a digitised paper test, and its FOCUS study is among the most deliberate bias investigations by any vendor in this index. What it costs you is flexibility, since Clarity and Thrive are dedicated calibrated hardware with no remote option and no named EHR integration. BrainCheck is the more deployable and commercially transparent choice: it runs on any tablet with proven remote equivalence, names the exact CPT codes and reimbursement path openly, and integrates with Epic and athenahealth, at the cost of being a normed digital battery rather than a model. If your failure mode is regulatory defensibility and demographic validity, start with Cognivue. If your failure mode is deployment friction and getting the workflow reimbursed, start with BrainCheck.
- The reimbursement path is published, not gated: BrainCheck names the specific CPT codes including 96136, 96138, 96132, and 99483, the 16 minute minimum for time based codes, and telehealth eligibility, in an annually updated guide, graded A on commercial transparency where Cognivue publishes no code level guidance and grades B.
- Flexible delivery with evidence behind it: runs on any tablet or smartphone, in clinic or remote, and a published finding that remote self administration is statistically indistinguishable from coordinator led sessions, where Cognivue requires dedicated calibrated hardware and grades C on deployment.
- Named EHR integration: live links to Epic and athenahealth with results in the chart, graded B on interoperability, where Cognivue generates a one page report at the device and grades C.
- The regulatory foundation of the category: Cognivue holds the De Novo classification DEN130033, the first FDA cleared computerised cognitive test, which created the pathway later entrants were cleared into, graded A on regulatory status where BrainCheck grades B on inconsistent cleared, registered, and approved language.
- More than a digitised battery: adaptive psychophysics dynamically calibrates to each patient's visual and motor abilities across more than 130,000 data points, graded B on AI centrality where BrainCheck's normed digital battery grades C.
- A bias study designed as one: the FOCUS study enrolled 452 participants across six US sites stratified by age, education, sex, race, and ethnicity, graded A on governance where BrainCheck grades B without a subgroup breakdown.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BrainCheck and Cognivue are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BrainCheck | Cognivue |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2015 | Not recorded |
| Headquarters | Austin, Texas, United States | Rochester, New York, United States |
| Website | braincheck.com | cognivue.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards BrainCheck its top capability grade on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and HIPAA and BAA Posture. Set against Cognivue, BrainCheck grades higher on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Cognivue its top capability grade on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and FDA and Regulatory Status. Set against BrainCheck, Cognivue grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose BrainCheck or Cognivue?
On the axes where the AI Health Index separates them, BrainCheck grades higher on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and EHR and Interoperability Depth, and Cognivue grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do BrainCheck and Cognivue differ most?
The widest separation the AI Health Index records between BrainCheck and Cognivue is on HIPAA and BAA Posture, where BrainCheck grades A and Cognivue grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do BrainCheck and Cognivue grade the same?
The AI Health Index grades BrainCheck and Cognivue the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have BrainCheck and Cognivue not disclosed?
At the last review, at least one of BrainCheck and Cognivue published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are strong, candid records: each grades A on autonomy for prominently stating it is an adjunctive tool and not a stand alone diagnostic, and each reports its own unflattering numbers, BrainCheck the weaker 64 percent true positive rate for the MCI group, Cognivue its modest r=0.38 correlation with the MoCA. Both grade A on clinical evidence from independent, peer reviewed validation.
The split is structural: Cognivue is the regulatory originator with the stronger bias study but the most capital intensive deployment, dedicated hardware with no remote option; BrainCheck is the more flexible and commercially legible product but a digitised battery rather than a computational model. Neither publishes a security attestation such as SOC 2 or a BAA. Neither publishes a device or licence price.